A phase II trial of TPI 287 in patients with metastatic prostate cancer who have progressive neoplastic disease following treatment with one prior taxane regimen.
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2014
At a glance
- Drugs TPI 287 (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Cortice Biosciences
- 24 Jan 2012 Actual end date (1 Aug 2008) added as reported by ClinicalTrials.gov.
- 24 Jan 2012 Planned end date changed from 1 Dec 2008 to 1 Aug 2008 as reported by ClinicalTrials.gov.
- 24 Jan 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.